Neera Ravindran, MD

Neera Ravindran, MD

Chief Financial Officer

  • Bio
    Neera Ravindran is the Chief Financial Officer for Kriya Therapeutics. She joined Kriya from Vir Biotechnology where she served as Vice President, Head of Investor Relations & Strategic Communications. While at Vir, she led the company’s investor relations program, as well as scientific and strategic communications efforts, during a period of rapid growth and evolution as the company successfully discovered, developed and brought to market a leading monoclonal antibody to combat COVID-19, raised $345 million in an S-1 follow-on offering and grew from under $2 billion to $7 billion in market capitalization. Previously, Dr. Ravindran was Head of Investor Relations, North America at Roche/Genentech where she developed and executed the company’s North American investor relations strategy, including the American Depository Receipt program. Prior to that, she was Vice President of Investor Relations & Strategic Planning at The Medicines Company, where she led the organization’s investor relations program through multiple corporate development and FDA milestones, including four new product approvals and commercial launches, two company acquisitions and multiple equity and debt financings. Earlier in her career she served as a biotechnology equity research analyst at Piper Jaffray & Company, and as an investment professional at Venrock, where she helped launch its first public equities fund. Dr. Ravindran completed her medical education at the Kasturba Medical College in Mangalore, India and earned an MBA from the Indian School of Business in Hyderabad, India.